



Total endovascular treatment for extent type 1 and 5
thoracoabdominal aortic aneurysmsGabriele Piffaretti, MD, PhD,a Federico Fontana, MD,b Marco Franchin, MD,a Alessandro Bacuzzi, MD,c
Walter Dorigo, MD,d Patrizio Castelli, MD,a and Matteo Tozzi, MDaABSTRACT
Objective: The study objective was to describe the results of thoracic
endovascular aortic repair with the intentional coverage of the celiac artery
and distal supramesenteric landing zone for extent type 1 and type 5
thoracoabdominal aortic aneurysms.
Methods: Inclusion criteria were thoracic endovascular aortic repair with celiac
artery coverage to treat elective or urgent extent type 1 and 5 thoracoabdominal
aortic aneurysms. Primary end points were in-hospital and follow-up survival,
freedom from aortic-related mortality, and freedom from reintervention.
Results: Thoracoabdominal disease extent was type 1 in 12 patients (71%) and
type 5 in 5 patients (29%). Urgent repair was performed in 4 patients (23.5%).
Primary technical success was 100%. Early mortality and visceral ischemia did
not occur. Permanent spinal cord ischemia rate was 6% (n¼ 1). Follow-up ranged
from 3 to 120 months (interquartile range, 12-36.5). Survival estimate was
85%  9% (95% confidence interval, 67-94) at 1 year and 49%  17%
(95% confidence interval, 21-78) at 5 years. Cumulative freedom from
aortic-related mortality was 94%, and estimated freedom from reintervention at
1 and 5 years was 93%  7% (95% confidence interval, 68-99). Neither type
1 endoleaks nor distal stent-graft migration causing superior mesenteric artery
occlusion was detected.
Conclusions: Thoracic endovascular aortic repair with intentional coverage of ce-
liac artery for extent 1 and 5 thoracoabdominal aortic aneurysms had satisfactory
results in selected patients at high risk for open repair. Visceral ischemia did not
occur, but spinal cord ischemia is still high at 6%. At midterm follow-up, neither
endoleak development nor aortic reintervention was related to the inadequate
distal landing zone. Follow-up survival is satisfactory and comparable to open
repair. (J Thorac Cardiovasc Surg 2017;154:1487-96)From aVascular Surgery, bInterventional Radiology, and cAnesthesia and Palliative
Care, Department Medicine and Surgery, Circolo University Teaching Hospital,
University of Insubria School of Medicine, Varese, Italy; and dVascular Surgery,
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Central Message
TEVARwith intentional coverage of the CA for
extent 1 and 5 TAAAs had results comparable
to those for conventional OR.Perspective
Visceral involvement of the aneurysmal disease
often is a prohibitive factor for TEVAR using
standard SG because of the proximity of the
mesenteric circulation. In selected cases, TE-
VAR using standard SG with the coverage of
the CA may be a viable technique for patients
who may not tolerate complex and risky OR.See Editorial Commentary page 1497.Thoracic endovascular aortic repair (TEVAR) has demon-
strated better results than open repair (OR) for descending
thoracic aortic aneurysms.1 However, the visceral involve-
ment of the aneurysmal disease often is a prohibitivefactor for TEVAR using a standard stent-graft (SG)
because of the proximity of the mesenteric circulation
and anatomically inadequate distal sealing zone. Only
few centers of excellence have published acceptable oper-
ative mortality rates less than 10% after OR for thora-
coabdominal aortic aneurysms (TAAAs)2-4; in the ‘‘real
world’’ practice, OR for TAAAs is still plagued by a
mortality rate up to 22%.5is QR codewill take
appendix for this
ery c Volume 154, Number 5 1487
Abbreviations and Acronyms
ARM ¼ aortic-related mortality
CA ¼ celiac artery
CI ¼ confidence interval
CSFD ¼ cerebrospinal fluid drainage
CTA ¼ computed tomography angiography
IQR ¼ interquartile range
OR ¼ open repair
SCI ¼ spinal cord ischemia
SG ¼ stent-graft
SMA ¼ superior mesenteric artery
SVS ¼ Society for Vascular Surgery
TAAA ¼ thoracoabdominal aortic aneurysm
TEVAR ¼ thoracic endovascular aortic repair
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Hybrid reconstructions, TEVAR with fenestrations, or
parallel-graft techniques have been used as alternative
techniques especially for patients at high risk for OR, but
even these are physically and technically demanding
procedures or still have unproven durable long-term
results.6,7 Total visceral reconstruction (open, hybrid,
endovascular with fenestrations) is unavoidable in
most TAAAs: however, in extent type 1 and type 5,
TEVAR using standard SG with the coverage of the celiac
artery (CA) can be a less complex and strenuous
procedure.8-11
The aim of this article was to report our results with total
endovascular repair of extent type 1 and type 5 TAAAs
using standard TEVAR with the intentional coverage of
the CA and supramesenteric distal landing zone.MATERIALS AND METHODS
Study Design and Cohort of Patients
This is a single-center, observational descriptive study. Starting in June
2006, all patients treated with TEVAR for TAAAwere identified (Figure 1).
For the final analysis, the end of the study was December 1, 2016.
The present cohort includes the following:
 TEVAR with coverage of the CA to treat elective (diameter60 mm) or
urgent extent type 1 and type 5 TAAAs in patients considered unfit for
OR.
The cohort does not include the following:
 TEVARwith CA coverage to treat elective or urgent saccular juxtaceliac
aortic lesions;
 distal SG extension with CA coverage to treat elective or urgent type 1b
endoleak;
 TAAA treated with OR or hybrid reconstruction (TEVAR with
retrograde visceral vessels revascularization); and
 TAAA treated with branched/fenestrated SG, or with ancillary
techniques such as chimney/snorkel/periscope.
All clinical and procedural data were prospectively collected and
recorded into a computerized database. Information about demographics,
comorbidities, medical and surgical history, operative details and
postoperative events during the hospital stay, and follow-up was registered.1488 The Journal of Thoracic and Cardiovascular SurInformed consent was signed by all patients. Approval for this specific
study was obtained by the local Institutional Review Board according to
the National Policy in the matter of Privacy Act on retrospective analysis
of anonymized data.
Aortic Assessment, Treatment Protocol, and
Follow-up
This type of TEVAR was performed if the distal SG landing zone was
less than 41 mm in diameter and 10 mm at least in length from the origin
of the superior mesenteric artery (SMA) (Figure 2, A-C). Meticulous
attention was paid to evaluate the mesenteric circulation: Both the SMA
and the portal vein had to be patent. Thus, exclusion criteria were
morphologic and clinic-pathologic:
 aortic disease extent involving both the CA and the SMA;
 larger (>41 mm) aortas;
 SMA occlusion or signs/symptoms of abdominal angina, or portal vein
occlusion; and
 chronic dissection with very narrowing true lumen.
For the gastroduodenal collateral network between the SMA and the
CA, a preoperative selective arteriogram was eventually performed us-
ing the temporary CA balloon occlusion test to further delineate the ex-
istence of these collaterals when computed tomography angiography
(CTA) did not elucidate them clearly.12,13 Triple-phase CTA follow-
up was performed at 1, 6, and 12 months, and on an annually basis
thereafter (Figure 3, A, B, C1-2). Maximum aortic diameter was
measured on preoperative CTA and on the most recent postoperative
CTA.Operative Technical Details
All operations were performed in the operating room, using general
anesthesia in all patients. According to the cardiovascular risk of the
patient, general anesthesia was performed using midazolam 0.01 to
0.1 mg/kg, propofol 1 to 2 mg/kg or thiopental sodium 2 to 4 mg/kg,
fentanyl 1 to 2 g/kg, and rocuronium 0.6 to 1.2 mg/kg. General anes-
thesia was maintained using halogenated gases. The management of
spinal cord ischemia (SCI) prevention involved different aspects, which
are in agreement with the most recent position statement of the Euro-
pean Association for Cardio-Thoracic Surgery vascular domain.14
Briefly, in elective cases, antiplatelets and anticoagulants were sus-
pended appropriately to limit the bleeding risk for cerebrospinal fluid
drainage (CSFD) positioning. The CSFD catheter was inserted intrao-
peratively and maintained for at least 72 hours. Left subclavian artery
revascularization was performed in the presence of a stable clinical
condition, when the dominant left vertebral artery had been confirmed,
or in the presence of previous abdominal aortoiliac surgery, patent
arteriovenous access for hemodialysis, patent left internal thoracic ar-
tery in patients already submitted to coronary artery bypass grafting,
and left arm ischemia/impotence. A combination of vasoactive agents
infusion (dopamine, 3-5 g/kg/min, noradrenaline 0.01-0.1 g/kg/min,
nitroglycerin 0.5-5 g/kg/min), fluid intake, and diuretics (bolus of furo-
semide 10-20 mg or 50-150 mg/die of mannitol 5% infusion) was used
to maintain a stable hemodynamic condition throughout the entire pro-
cedure, and the postoperative course: Mean arterial pressure was main-
tained at 80 mm Hg or greater, central venous pressure was maintained
at less than 12 mm Hg, and transfusions were used to preserve hemo-
globin level 10 g/dL or greater. Generally, SGs were deployed sequen-
tially: the longest possible SG proximally and the shorter one distally,
to have the best deployment control as possible at the SMA border.
CA occlusion was always performed before the deployment of the distal
SG. In all patients, we used an endovascular plug that was delivered
through the transfemoral approach. Both the SG and the endovascular
plug were oversized by 20%, according to the diameter of the normalgery c November 2017
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FIGURE 1. CONSORT diagram indicating all patients with descending and thoracoabdominal aneurysms during the period of study, including the patient
population from whom this series was derived. BMT, Best medical treatment; TAAA, thoracoabdominal aortic aneurysm.




aorta at the landing zones and the diameter of the CA, respectively. All
patients were admitted to the intensive care unit postoperatively. Labo-
ratory analyses included blood count, coagulation serum lactic acid
concentration, and full hepatic function panel on a daily basis. Graft
materials are reported in the Appendix.
Definition
Comorbidities were defined according to the Society of Thoracic
Surgeons adult database.15 Morphologic characteristics and outcomes
were defined accordingly to the European Association for
Cardio-Thoracic Surgery/European Society for Cardio-Vascular Sur-
gery best practice guidelines for reporting treatment results in the
thoracic aorta or the Society for Vascular Surgery (SVS) ad hoc com-
mittee on TEVAR reporting standards.16,17 In particular, urgency of
the intervention was defined accordingly to the European System forThe Journal of Thoracic and CarCardiac Operative Risk Evaluation classification.18 Primary technical
success was defined as the successful deployment of the SG with the
exclusion of the aortic lesion in the absence of surgical conversion to
OR or death at 24 hours or less. SCI was classified accordingly to
the SVS grading system.16 The proximal landing zone of the thoracic
SG was defined following the ‘‘arch map’’ classification.16 Follow-up
index described follow-up completeness at the given study end date
as the ratio between the investigated and the potential follow-up
period.19 TEVAR-related mortality included deaths due to aortic
rupture, surgical conversion, or complications of TEVAR unsolved by
additional procedures. Aneurysm sac shrinkage was defined as 1 cm
or greater maximum aortic diameter reduction from the preoperative
measurement. Our analysis evaluated in-hospital mortality and
follow-up survival, freedom from aortic-related mortality (ARM), and
freedom from reintervention.diovascular Surgery c Volume 154, Number 5 1489
FIGURE 2. Preoperative CTA of a Crawford type 1 TAAA: Multiplanar reconstruction (A) shows the length (black dashed line) of the distal landing zone
(arrow) at the supramesenteric artery. Axial CTA (B) shows the sizing at distal landing zone. Intraoperative completion angiogram (C) shows the additional
(14 mm) tapered distal neck (brace) gained with the intentional coverage of the origin of the CAwith the endovascular plug (dashed circle). In this case, the
take-off of the CAwas located at the transition point of the tapered area (arrow) at the final angiogram. Final angiogram also confirms the revascularization
of the common hepatic artery through the collateralization of the SMA (dashed arrow).




Clinical data were prospectively recorded and tabulated in Microsoft
Excel (Microsoft Corp, Redmond, Wash) database. Statistical analysis
was performed with SPSS, release 23.0 for Windows (IBM SPSS Inc,
Chicago, Ill). Categoric variables were presented using frequencies
and percentages, and continuous variables were presented with
mean  standard deviation and interquartile range (IQR); otherwise,
medians with range were applied. Wilcoxon signed-rank test was used to
evaluate the difference in blood test results before and after TEVAR.
Cumulative survival, freedom from ARM, and freedom from
reintervention rates were estimated using the Kaplan–Meier
method  standard error and 95% confidence interval (CI).
RESULTS
General Population and Cohort Data
During the study period, we evaluated 283 patients with
arch/descending/thoracoabdominal aortic disease. Of this
cohort, 47 patients (17%) had a TAAA: Total endovascular
repair using TEVAR with intentional coverage of the CA
was performed in 17 patients (overall TEVAR ¼ 10%;
overall TAAAs ¼ 36%). Of these 17 TAAAs, 16 were
degenerative atherosclerotic aneurysms and 1 was
dissection-related aneurysm. No connective tissue
disorder–related aneurysm was treated. During the same
period, the remainder of TAAAs were treated with OR
(n ¼ 12, 25%), hybrid reconstruction (n ¼ 9, 19%),1490 The Journal of Thoracic and Cardiovascular SurSG with branch/fenestrations (n ¼ 5, 11%), and chimney/
periscope (n ¼ 4, 8.5%). Three patients with extent type
1 or 5 did not undergo operation because of prohibitive
operative risk (free rupture in octogenarian n ¼ 2, cancer
n ¼ 1). We treated 9 women (53%); overall, patients’
mean age was 74  7 years (range, 59-86; IQR, 69-79).
Demographics, comorbidities, and risk factors are reported
in Table 1. Thoracoabdominal disease extent was type 1 in
12 patients (71%) and type 5 in 5 patients (29%). The CA
was patent in all cases, but 4 (24%) had a preocclusive
ostial stenosis; 13 patients (76%) had a complete CA in
the form of a gastro-hepato-splenic trunk, and 2 patients
(12%) had the right hepatic artery arising from the SMA.
Adequate collateral network was present in all patients.
The mean diameter of the distal sealing zone at the origin
of the SMA was 31  6.5 mm (range, 25-40 mm;
IQR, 25-36). By covering the CA origin, we obtained
a mean sealing zone of 18  8 mm (range, 10-32 mm;
IQR, 12-20).Operative Details
Urgent repair was performed in 4 patients (23.5%)
because of thoracic pain and signs of impending rupture
at CTA (n ¼ 2) or contained rupture (n ¼ 2). Intraoperativegery c November 2017
FIGURE 3. Preoperative (A) CTA with volume-rendering 3-dimensional reconstruction of a type 1 thoracoabdominal aortic aneurysm. Postoperative
(B) follow-up CTA: thoracoabdominal TEVARwith intentional coverage of the CA. Note the patency of the CA (A, C1, arrow), its occlusion (B, C2, arrow)
with the endovascular plug, and the absence of type 1b endoleak (B, dashed arrow).




technical details are shown in Table 2. Briefly, CSFD was
inserted in all elective cases; the left subclavian artery
was revascularized in 3 patients (18%) using a bypass graft
from the left common carotid artery. We used only 1
vascular plug in each patient to occlude the CA. The
mean oversizing at the distal landing zone was
22%  4% (range, 15-30; IQR, 20-22).
Early Results
Primary technical success was 100%; conversion to OR
was never required. In-hospital mortality did not occur.
Occlusion of the CA was successful in all cases, along
with the exclusion of the TAAA. At final angiogram, there
were no type 1 or type 2 endoleaks from the CA, and the
SMA did not present filling defects. In all cases, adequate
collateralization was observed in the final angiogram. All
patients but 1 (94%) were extubated at the end of the
intervention; median intensive care unit stay was 1 day
(range, 1-8; IQR, 1-4.5). Blood panel showed significant
modifications between the preoperative and postoperative
values, as reported in Table 3. No visceral ischemia
requiring surgery occurred. Stroke was never observed.
Postoperative complication developed in 3 patientsThe Journal of Thoracic and Car(18%): SVS class 3c SCI (n ¼ 1, 6%), which did not
respond to increase vascular perfusion and rehabilitation
program; pneumonia (n ¼ 1), which was successfully
treated with antibiotics; and atrial fibrillation (n¼ 1), which
resolved using amiodarone. Mean hospitalization was
11  8 days (range, 4-29; IQR, 5-12).
Late Outcomes
All patients were discharged alive; 16 (94%) were
independently living at home. The mean follow-up was
36  25 months (range, 3-120; median, 24; IQR,
12-36.5), and the follow-up index was 0.8  0.2. All
patients had CTA follow-up at 1 month, 12 patients
(70%) had CTA follow-up at 12 months, 7 patients
(41%) had CTA follow-up at 36 months or more, and 3
patients (18%) had CTA follow-up at more than 60 months.
During the follow-up, 6 patients (35%) died after a median
of 35 months (range, 4-96). Causes of late death are
reported in Table 4. Kaplan–Meier estimate of survival
was 85%  9% (95% CI, 67-94) at 1 year and
49%  17% (95% CI, 21-78) at 5 years (Figure 4).
Cumulative freedom from ARM was 94%. A 73-year-old
extremely fragile woman developed an SG infection duediovascular Surgery c Volume 154, Number 5 1491











Atrial fibrillation 3 (18)






Ischemic heart disease 2 (12)
Risk factors








euroSCORE additive (mean  SD) 11.4  3 (IQR, 9-13)
euroSCORE logistic (mean  SD) 30.5  17.2 (IQR, 15.46-41.21)
euroSCORE II (mean  SD) 6.7  5.3 (IQR, 3.4-6.82)
n, Number; F, female; M, male; SD, standard deviation; IQR, interquartile range;
COPD, chronic obstructive pulmonary disease; AAA, abdominal aortic aneurysm;
AoS, previous aortic surgery; BMI, body mass index; eGFR, estimated glomerular
filtration rate; CVA, cerebrovascular accident; euroSCORE, European System for
Cardiac Operative Risk Evaluation.
TABLE 2. Technical details and intraoperative data
Variables n (%)
General anesthesia 17 (100)
Vascular access
Femoral 16 (94)
Iliac conduit 1 (6)
SG
Distal free-flow 4 (23.5)
Aortic coverage (cm mean  SD) 29  7 (IQR, 24-35)
2 SGs 14 (82)
3 SGs 3 (18)
CSFD 13 (76)
Duration (min mean  SD) 180  85 (IQR, 130-240)
Blood loss (mL mean  SD) 231  159 (IQR, 100-412.5)






Carotid-subclavian bypass 3 (18)
Iliac stent 2 (12)
Femoral endarterectomy þ patch 2 (12)
Right renal stent 1 (6)
EVAR 1 (6)
n, Number; SG, stent-graft; SD, standard deviation; CSFD, cerebrospinal fluid
drainage; IQR, interquartile range; PRBC, packed red blood cell; EVAR, endovascular
abdominal aortic repair.
















GPT (U/L) 18  13 32  22 .021
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to an aortoesophageal fistula 4 months after TEVAR. In this
case, an esophageal SG was implanted to prevent massive
fatal bleeding, but she died of sepsis shortly after this pro-
cedure. Estimated freedom from aortic-related events and
reintervention at 1 and 5 years was 93%  7% (95% CI,
68-99). Two events (12%) occurred: the mentioned aortoe-
sophageal fistula (at 4 months) and a type 3 endoleak
(at 72 months) that was successfully sealed off with an
additional SG. Sac shrinkage was observed in 10 patients
(59%). Both type 1 and type 2 endoleaks were not detected.
SG infolding at the distal sealing zone or caudal SG
migration causing SMA obstruction or abdominal angina
was never observed.(11-19.5) (13-52)










WBC, White blood cells; IQR, interquartile range; GOT, glutamate oxaloacetate
transaminase; GPT, glutamate pyruvate transaminase; LDH, lactic dehydrogenase.DISCUSSION
Extent type 1 and 5 are not infrequent among all TAAAs.
In large-volume aortic centers, the mean prevalence was
25% with a reported range of 23% to 37%.2-4,8 Surgical
decision making is a key element in surgery, and thus any1492 The Journal of Thoracic and Cardiovascular Surtype of intervention that may ameliorate outcomes after
TAAA repair is welcome. There are 2 main reasons why
we considered TEVAR with the intentional coverage of
the CA a valid alternative especially for patients at high
risk for OR: the mean mortality rate of 11% reported by
centers of excellence after OR for type 1 and 5 TAAAs,
and the encouraging results of the series that reported this
specific TEVAR strategy.8-13,20-23gery c November 2017
TABLE 4. Causes of mortality during the follow-up
Gender Age TAAA (extent) PoC Cause POM (mo)
M 65 5 Uneventful AMI 96
F 86 1 Uneventful AKI 12
M 76 5 Pneumonia Traumatic cerebral hemorrhage 36
F 73 1 Uneventful Sepsis 4
F 71 1 Uneventful Colorectal cancer 24
M 81 5 Uneventful Respiratory failure 37
TAAA, Thoracoabdominal aortic aneurysm; PoC, postoperative course; POM, postoperative mortality; M, male; AMI, acute myocardial infarction; F, female; AKI, acute kidney
injury.




A recent propensity-matched score analysis comparing
TEVAR and OR for TAAAs reported an operative mortality
in the range of 6.3% to 7.7%.24 Such analysis did not strat-
ify for TAAA extent; this is not an indifferent detail, and not
only for OR. A recent publication by Schaffer and col-
leagues25 focusing on the use of TEVAR in different clinical
scenarios showed that patients with more complex aortic
disease required more complex procedures, with worse re-
sults. This means the simpler the procedure, the better the
results. Although our series is a selected cohort of patients
at high risk for OR, standard TEVAR with the intentional
coverage of the CA brought satisfactory results if compared
with the predicted 6.6% mortality rate.
Undeniably, there are important concerns regarding the
outcomes of TEVAR for TAAAs. The first concern is
aortic-related failures: The need for aortic reintervention
was 12% in our experience, which is clearly higher than
the 2.6% to 4.6% after OR reported in the largest
experiences.2,4 After reviewing the literature data on
TEVAR with intentional coverage of the CA, the need forFIGURE 4. Kaplan–Meier graphs show the estimated survival in patients
treated with TEVAR and intentional coverage of the CA for extent type 1
and type 5 thoracoabdominal aortic aneurysms. CI, Confidence interval.
The Journal of Thoracic and Caraortic reinterventionwas still high at 8.6% (Table 5).8-13,20-23
However, reintervention was always performed with another
endovascular intervention, the redo-related operative mortal-
ity was absent, and reintervention did not influence follow-up
survival.8-13,20-23 Second, the primary goal of TEVAR is
freedom from ARM. Our experience was not exempt from
this risk, but the 94% cumulative freedom from ARM is
satisfactory, especially if we take into account the advanced
mean age and the high-risk profile for OR of this cohort.2-
4,6,26 This is a result that finds support from Patel and
colleagues,27 who reported a significant survival benefit of
TEVAR versus OR for high-risk patients. Last, but not least,
survival in the follow-up is a concern:Although the results are
not robust enough to be considered long-term results, the esti-
mated survival at 5 years of 49% is satisfactory for these
high-risk patients if compared with the 47% reported in a
large database analysis.25
When covering the CA to extend the distal sealing zone
of TEVAR, visceral ischemia is an important concern.22,28
Although in our review (Table 5) this complication was
never reported in 63% of the series on TAAAs, when this
occurred, mortality was ascribed to ‘‘shock liver.’’13,20,22
We maintained an alert vigilance during the entire
postoperative period for 2 main reasons: (1) the
unpredictable occurrence and clinical manifestation of
visceral ischemic complications and (2) the significant
increase in the postoperative period of liver enzymes,
white blood cells, and lactates, all potential markers of
splanchnic ischemic hypoperfusion. These modifications
did not develop homogeneously and did not have a
consensual trend. Similar to previous experience, we were
not able to identify cutoff values that would prompt
emergency reintervention to prevent acute visceral
complications.13,20 Although these remarkable blood test
modifications did not translate into severe ischemic
complications, we can draw 2 observations. On the one
hand, they confirm that the intentional coverage of the CA
should not be considered an ‘‘innocent’’ procedure. On
the other hand, in these circumstances any urgent surgical
reintervention should not be dictated solely by blood test.
The distal landing zone at the supramesenteric border
raised another important concern, which is the sealingdiovascular Surgery c Volume 154, Number 5 1493
TABLE 5. Thoracic endovascular aortic repair with intentional coverage of the celiac artery and supramesenteric distal sealing zone: Literature
summary






















Siegenthaler and colleagues8 12 3.2 n.e. 0 0 17 80% n.e. n.e. 0 n.e.
Brinster and colleagues9 6 2 0 0 0 30.5 100 33.3 16.6 0 0
Rose and colleagues10 18 4.9 6 11 11 38 78 27 11 5.5 0
Kato and colleagues11 5 n.e. 0* 0 0 20.7 n.e. 20 20 0 0
Waldenberger and colleagues12 10 n.e. 10 0 0 21 90 0 10 0 0
Mehta and colleagues13 31 13.5 6 6 6 15 n.e. 16 6 0 0
von Allmen and colleagues19 5 2.5 20 0 20 13 80% 0 0 0 0
Belenky and colleagues21 7 n.e. 0 0 0 n.e. 86% 42.8 14.3 0 0
Leon and colleagues22 16 3.7 18.7 12.5 6.25 8.7 n.e. 0 0 0 0
Delle and colleagues23 9 7.5 0 11.1 0 13-56 100% 0 0 0 0
n, Number; TEVAR, thoracic endovascular aortic repair; SCI, spinal cord ischemia; Redo, aortic reintervention; T1b, type 1b endoleak occurrence; ORC, open repair conversion;
ARM, aortic-related mortality; n.e., not possible to be extrapolated.
Acquired: Aorta Piffaretti et alA
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durability of this strategy because of the potential develop-
ment of type 1b endoleak. Specific technical details have
been infrequently specified in previous reports, but to use
this technical strategy, one should take into account 2 as-
pects of this distal sealing zone: First, this segment of
visceral aorta is short but frequently tapered at the origin
of the SMA. Second, the oversize cutoff for visceral artery
overstenting in a TAAA treated with a standard SG is a
different concept than graft replacement during OR.
Because of this morphologic characteristic and oversizing
with the currently available SGs, a distal seal has been
accomplished in most type 1 and 5 TAAAs, which would
have invariably needed more extensive visceral graft
replacement during OR.8 Although type 1b endoleak was
never detected in our series, it was reported in 5.2% of
the published cases: however, none presented with rupture
and almost all endoleaks were successfully sealed off
with an SG extension without additional mortality.9-13,21
Another potential problem when the distal landing zone
approximating the upper limit of the SMA could be the
onset of abdominal angina during the follow-up. In the
published reports of TEVAR with intentional CA coverage
and supramesenteric distal landing zone, abdominal angina
was determined by distal migration of the SG or the partial
coverage of the SMA origin by a stent strut of the SG.10,12,13
This event did not occur in our experience; however, in the
rare cases in which it occurred, SMA stenosis was
effectively treated with direct stenting and led to the
complete resolution of the symptoms. Nonetheless, any
subsequent mesenteric bypass surgery would not be
precluded if another failure eventually occurs.
Regardless of the strategy adopted, patients with extent
type 1 and 5 TAAA need extensive aortic treatment and
are at high risk for SCI. Greenberg and colleagues6 reported
an SCI hazard of 21 after TEVAR in these types of TAAAs.1494 The Journal of Thoracic and Cardiovascular SurIntercostal artery occlusion may not be sufficient per se to
induce SCI, but those between T8 and L2 may play a critical
role for the spinal perfusion.29 Even if our technical strategy
may restrict the aortic coverage when compared with open/
hybrid/branched repair, in these types of TAAAs the
coverage of this critical area is still essential. In our series,
SCI is still substantial at 6% despite the best efforts to refine
treatment strategy and the use of technical adjuncts. This is
higher than the mean 4.6% by reviewing series enrolling
more than 10 cases of intentional coverage of the CA, but
neither aortic disease extent nor aortic coverage length
was clearly reported in that experiences.8,10,12,13 In regard
to SCI, a staged approach has been proposed to limit the
ischemic insult when extensive aortic coverage is
planned.29,30 We did not test this alternative strategy. This
approach lacks strong evidence so far, but because of the
encouraging results, it deserves attention for a possible
application.
This technical strategy is not the only one we used for
TAAA repair: OR, hybrid reconstructions with visceral
vessels debranching, and total endovascular solution with
fenestrations or parallel grafts have been tailored
accordingly to the operative risk of the patient and the aortic
disease. Although satisfactory results have been reported
with all the alternative techniques, no full comparative
analyses exist.6,24,26 Of the only 2 series that included
hybrid TAAA repair and TEVAR with the intentional
coverage of the CA, the results obtained by Siegenthaler
and colleagues8 with isolated TEVAR highlighted the
importance of the minimally possible invasiveness to obtain
the least possible morbidity.
Study Limitations
First, this is a retrospective study, and the cohort is small
in numbers. Second, the study has a sampling bias: OR andgery c November 2017




hybrid, fenestrated, or parallel SGs arms were not included
for comparison because of the small number of patients in
each treatment arm, but this reflects the careful selection
process for this type of procedure. Last, multivariate
analysis was not performed, but it would have been
misleading because of the cohort size. Despite these
limitations, inclusion criteria make the cohort
homogeneous, the compliance to follow-up was high, and
outcomes adhered systematically to the proposed guidelines
that compare well with those of other studies.
CONCLUSIONS
TEVAR with intentional occlusion of the CA and
supramesenteric distal landing zone to treat extent type 1
and 5 TAAAs showed encouraging results in selected
patients at high risk for OR. In-hospital mortality was better
than expected by score prediction, visceral ischemic injury
was evident only on an enzymatic level, and follow-up
survival is comparable to OR. At midterm follow-up,
neither endoleak development nor aortic reintervention
was related to the inadequate distal landing zone. Larger
cohort or comparative experiences comprising all the
different techniques to treat these TAAAs are expected for
more comprehensive analyses. Nevertheless, this is a
technical strategy that should be contemplated as a possible
valid alternative in selected patients with extent type 1 and 5
TAAAs.
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APPENDIX.
STENT-GRAFT
Excluder/TAG/C-TAG (WL Gore & Associates, Flagstaff,
Ariz)
Talent/Valiant/Captivia (Medtronic Vascular, Santa
Rosa, Calif)
Relay (Bolton Medical, Sunrise, Fla)
LEFT SUBCLAVIAN ARTERY MANAGEMENT
Occlusion plug, Amplatzer (St Jude Medical, St Paul,
Minn)
PERIPHERAL STENT
Renal, Genesis Blue (Cardinal Health, Baar,
Switzerland)
Iliac, S.M.A.R.T (Cardinal Health)
CONVENTIONAL SURGICAL GRAFT
Bypass, Propaten (WL Gore & Associates)
CEREBROSPINAL FLUID DRAINAGE
Duet (Medtronic Vascular)
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